Kite Pharma is a pioneering biotechnology company specializing in cancer immunotherapy, specifically engineered T cell therapy. Founded in 2009, Kite has been at the forefront of developing innovative treatments that use genetically modified immune cells to target and destroy cancerous tumors. The company operates in the highly specialized field of cell therapy, aiming to fundamentally change the way cancer is treated.

Kite's primary clients are patients suffering from various forms of cancer, particularly those who have not responded to traditional treatments like chemotherapy. The company serves a global market, with a focus on regions with advanced healthcare infrastructure.

Kite's business model revolves around research and development, clinical trials, and the commercialization of its therapies. Revenue is generated through the sale of its approved therapies, licensing agreements, and partnerships with other pharmaceutical companies.

The company's mission is to bring potentially lifesaving therapies to patients who need them most, with the ultimate goal of curing cancer. Kite's innovative approach has positioned it as a leader in the field, making significant strides in cancer treatment and offering hope to millions of patients worldwide.

Keywords: cancer immunotherapy, T cell therapy, genetically modified cells, tumor targeting, biotechnology, clinical trials, cancer treatment, cell therapy, lifesaving therapies, pharmaceutical partnerships.